Pollution-spike warnings tied to each asthma patient's own action plan
TL;DR Wheezealert warns asthma and COPD patients a few days before pollution spikes near their home and reminds them what their own doctor told them to do. It blends licensed street-level forecasts with each patient's logged symptoms and inhaler use. Pharma patient programmes and hospital chains pay, and doctors enrol patients. It supports care and never changes treatment.
India had about 3.79 crore people with asthma and 5.53 crore with COPD in 2016, and air pollution caused over half the COPD burden[1]. Pollution was linked to 16.7 lakh deaths in 2019[2].
Bad-air weeks fill emergency rooms. At AIIMS Delhi, higher PM2.5 was linked to 19.5% more adult breathing emergencies over the next week[3]. A Safdarjung Hospital study found no PM2.5 link and pointed to sulphur dioxide instead[4], so check both or ask a pulmonologist. In Pune, nebuliser sales climbed three to four days after PM2.5 spikes[5], which means there is a window to act.
Do patients use that window? Rarely. Most have an inhaler and a half-remembered verbal plan, and the news gives a city AQI, not a personal nudge to take the preventer properly this week.
What it does, in regulatory terms: monitoring and decision support. Wheezealert does not diagnose, prescribe or change treatment. It repeats the plan the patient's doctor wrote and says when to call that doctor. CDSCO's 2026 guidance treats patient-specific disease alerts as device software, not wellness[6], so expect Class A or B with a clinician involved and ask for a classification.
A pulmonologist enrols the patient and enters their written action plan. The patient taps twice a day to log symptoms and reliever puffs. With consent, Wheezealert pulls forecasts for home and work, and a model weighs them against the patient's own recent reliever use, which predicts trouble far better than pollution alone[7]. When risk climbs, a Hindi or English message arrives three days ahead. Doctors get a weekly list of patients whose reliever use has jumped.
The seed planned its own hyperlocal sensor network. That data is now cheap from free government forecasts and big-tech paid APIs, so I moved the effort to the patient side.
Users are diagnosed asthma and COPD patients in polluted cities, many of them older and relying on a family member's phone. Pulmonologists are the gatekeepers. Pharma respiratory brands are the main payers, and one large drugmaker's free patient platform shows an AQI reading but sends no alerts[8]. Hospital chains with respiratory clinics come second, paying per site or per patient. A consumer tier at ₹1,000–3,000 a year is my assumption and stays secondary.
Street-level forecasts are a commodity now. One big-tech air-quality API covers India at 500-metre resolution with 96-hour forecasts[9], at US$0.25–5 per 1,000 calls (about ₹24–484) depending on volume[10]. A 2023 study of 13,202 inhaler-sensor users showed pollution adds a small but real signal on top of personal reliever use[7]. The DPDP Rules of November 2025 set the consent terms for location and health data.
No source sizes a market for pollution alerts aimed at asthma and COPD patients. Here's a rough bottom-up - if 0.1–0.5% of the roughly 9.3 crore patients[1] paid ₹1,000–3,000 a year then revenue would be about ₹9–140 Cr by my arithmetic, and uptake is untested. Adjacent: one market research firm puts India's air-quality monitoring market at US$180.51M in 2025[11], mostly government hardware.
A US smart-inhaler company, now owned by a big respiratory-device maker, pairs inhaler sensors with an app and supplied the US data behind the reliever-use findings[7]. A Bengaluru climate-data startup sells hyperlocal air and pollen data to pharma and health apps[12], so it's a partner or a rival. Indian air-sensor networks run low-cost sensors across cities with no patient product. The drugmaker's patient platform[8] shows pharma interest without alerts. Nobody links forecasts to individual action plans through doctors.
| Difficulty | Moderate (43/100) |
| Starting capital | ₹1.55–2.8 Cr |
| Time to launch | 6–12 months |
The data is bought, not built. The hard parts are selling, since pharma sponsors move through brand, medical and compliance teams and doctors enrol patients one at a time, and building a model that stays quiet enough that patients don't mute it.
Yes. Patient-specific alerts count as medical device software here, so sort the paperwork before launch.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't let AI change anyone's treatment. It repeats the doctor's own plan and tells the patient when to call, and that's where it stops.
Want to work out the AI layer for Wheezealert? Talk to Yash →
Here's what can go south -
The useful product is a patient companion tied to doctors' plans, not another pollution map. The world has enough of those. I'd back a founder with links to pulmonologists or pharma respiratory teams. If your plan rests on owning sensors then rethink it, because the data is already cheap. Prove first, with 40 patients and two clinics, that people keep logging for three weeks.
My estimate is ₹1.55–2.8 Cr, covering the forecast data, the app, a classification request and the first pilots with clinics. The kit has the line-by-line breakdown.
Most likely yes. CDSCO treats patient-specific disease alerts as device software, so ask for a classification before launch, and plan your DPDP consent flows for location and health data.
Yes, and polluted cities everywhere have the same problem. Air-quality forecasts are available in many countries, but check how your own regulator treats health alert software first.
The free Wheezealert validation kit has the line-by-line capital breakdown, the effort scoring, the CDSCO and data-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for pulmonologists and pharma teams, and 5 assumptions to test. Download the kit →
Thinking of building Wheezealert or something like it? The make-or-break bit is getting a pharma sponsor and two hospitals to back a pilot that shows patients keep logging, and that's the kind of thing I help founders with. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.